Cargando…

In-silico simulated prototype-patients using TPMS technology to study a potential adverse effect of sacubitril and valsartan

Unveiling the mechanism of action of a drug is key to understand the benefits and adverse reactions of a medication in an organism. However, in complex diseases such as heart diseases there is not a unique mechanism of action but a wide range of different responses depending on the patient. Explorin...

Descripción completa

Detalles Bibliográficos
Autores principales: Jorba, Guillem, Aguirre-Plans, Joaquim, Junet, Valentin, Segú-Vergés, Cristina, Ruiz, José Luis, Pujol, Albert, Fernández-Fuentes, Narcís, Mas, José Manuel, Oliva, Baldo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7018085/
https://www.ncbi.nlm.nih.gov/pubmed/32053711
http://dx.doi.org/10.1371/journal.pone.0228926
_version_ 1783497302238822400
author Jorba, Guillem
Aguirre-Plans, Joaquim
Junet, Valentin
Segú-Vergés, Cristina
Ruiz, José Luis
Pujol, Albert
Fernández-Fuentes, Narcís
Mas, José Manuel
Oliva, Baldo
author_facet Jorba, Guillem
Aguirre-Plans, Joaquim
Junet, Valentin
Segú-Vergés, Cristina
Ruiz, José Luis
Pujol, Albert
Fernández-Fuentes, Narcís
Mas, José Manuel
Oliva, Baldo
author_sort Jorba, Guillem
collection PubMed
description Unveiling the mechanism of action of a drug is key to understand the benefits and adverse reactions of a medication in an organism. However, in complex diseases such as heart diseases there is not a unique mechanism of action but a wide range of different responses depending on the patient. Exploring this collection of mechanisms is one of the clues for a future personalized medicine. The Therapeutic Performance Mapping System (TPMS) is a Systems Biology approach that generates multiple models of the mechanism of action of a drug. Each molecular mechanism generated could be associated to particular individuals, here defined as prototype-patients, hence the generation of models using TPMS technology may be used for detecting adverse effects to specific patients. TPMS operates by (1) modelling the responses in humans with an accurate description of a protein network and (2) applying a Multilayer Perceptron-like and sampling strategy to find all plausible solutions. In the present study, TPMS is applied to explore the diversity of mechanisms of action of the drug combination sacubitril/valsartan. We use TPMS to generate a wide range of models explaining the relationship between sacubitril/valsartan and heart failure (the indication), as well as evaluating their association with macular degeneration (a potential adverse effect). Among the models generated, we identify a set of mechanisms of action associated to a better response in terms of heart failure treatment, which could also be associated to macular degeneration development. Finally, a set of 30 potential biomarkers are proposed to identify mechanisms (or prototype-patients) more prone of suffering macular degeneration when presenting good heart failure response. All prototype-patients models generated are completely theoretical and therefore they do not necessarily involve clinical effects in real patients. Data and accession to software are available at http://sbi.upf.edu/data/tpms/
format Online
Article
Text
id pubmed-7018085
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-70180852020-02-26 In-silico simulated prototype-patients using TPMS technology to study a potential adverse effect of sacubitril and valsartan Jorba, Guillem Aguirre-Plans, Joaquim Junet, Valentin Segú-Vergés, Cristina Ruiz, José Luis Pujol, Albert Fernández-Fuentes, Narcís Mas, José Manuel Oliva, Baldo PLoS One Research Article Unveiling the mechanism of action of a drug is key to understand the benefits and adverse reactions of a medication in an organism. However, in complex diseases such as heart diseases there is not a unique mechanism of action but a wide range of different responses depending on the patient. Exploring this collection of mechanisms is one of the clues for a future personalized medicine. The Therapeutic Performance Mapping System (TPMS) is a Systems Biology approach that generates multiple models of the mechanism of action of a drug. Each molecular mechanism generated could be associated to particular individuals, here defined as prototype-patients, hence the generation of models using TPMS technology may be used for detecting adverse effects to specific patients. TPMS operates by (1) modelling the responses in humans with an accurate description of a protein network and (2) applying a Multilayer Perceptron-like and sampling strategy to find all plausible solutions. In the present study, TPMS is applied to explore the diversity of mechanisms of action of the drug combination sacubitril/valsartan. We use TPMS to generate a wide range of models explaining the relationship between sacubitril/valsartan and heart failure (the indication), as well as evaluating their association with macular degeneration (a potential adverse effect). Among the models generated, we identify a set of mechanisms of action associated to a better response in terms of heart failure treatment, which could also be associated to macular degeneration development. Finally, a set of 30 potential biomarkers are proposed to identify mechanisms (or prototype-patients) more prone of suffering macular degeneration when presenting good heart failure response. All prototype-patients models generated are completely theoretical and therefore they do not necessarily involve clinical effects in real patients. Data and accession to software are available at http://sbi.upf.edu/data/tpms/ Public Library of Science 2020-02-13 /pmc/articles/PMC7018085/ /pubmed/32053711 http://dx.doi.org/10.1371/journal.pone.0228926 Text en © 2020 Jorba et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Jorba, Guillem
Aguirre-Plans, Joaquim
Junet, Valentin
Segú-Vergés, Cristina
Ruiz, José Luis
Pujol, Albert
Fernández-Fuentes, Narcís
Mas, José Manuel
Oliva, Baldo
In-silico simulated prototype-patients using TPMS technology to study a potential adverse effect of sacubitril and valsartan
title In-silico simulated prototype-patients using TPMS technology to study a potential adverse effect of sacubitril and valsartan
title_full In-silico simulated prototype-patients using TPMS technology to study a potential adverse effect of sacubitril and valsartan
title_fullStr In-silico simulated prototype-patients using TPMS technology to study a potential adverse effect of sacubitril and valsartan
title_full_unstemmed In-silico simulated prototype-patients using TPMS technology to study a potential adverse effect of sacubitril and valsartan
title_short In-silico simulated prototype-patients using TPMS technology to study a potential adverse effect of sacubitril and valsartan
title_sort in-silico simulated prototype-patients using tpms technology to study a potential adverse effect of sacubitril and valsartan
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7018085/
https://www.ncbi.nlm.nih.gov/pubmed/32053711
http://dx.doi.org/10.1371/journal.pone.0228926
work_keys_str_mv AT jorbaguillem insilicosimulatedprototypepatientsusingtpmstechnologytostudyapotentialadverseeffectofsacubitrilandvalsartan
AT aguirreplansjoaquim insilicosimulatedprototypepatientsusingtpmstechnologytostudyapotentialadverseeffectofsacubitrilandvalsartan
AT junetvalentin insilicosimulatedprototypepatientsusingtpmstechnologytostudyapotentialadverseeffectofsacubitrilandvalsartan
AT seguvergescristina insilicosimulatedprototypepatientsusingtpmstechnologytostudyapotentialadverseeffectofsacubitrilandvalsartan
AT ruizjoseluis insilicosimulatedprototypepatientsusingtpmstechnologytostudyapotentialadverseeffectofsacubitrilandvalsartan
AT pujolalbert insilicosimulatedprototypepatientsusingtpmstechnologytostudyapotentialadverseeffectofsacubitrilandvalsartan
AT fernandezfuentesnarcis insilicosimulatedprototypepatientsusingtpmstechnologytostudyapotentialadverseeffectofsacubitrilandvalsartan
AT masjosemanuel insilicosimulatedprototypepatientsusingtpmstechnologytostudyapotentialadverseeffectofsacubitrilandvalsartan
AT olivabaldo insilicosimulatedprototypepatientsusingtpmstechnologytostudyapotentialadverseeffectofsacubitrilandvalsartan